Management of mycosis fungoides: Part 2. Treatment

Benjamin D. Smith, Lynn D. Wilson

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

Mycosis fungoides is a low-grade lymphoproliferative disorder of skin-homing CD4+ lymphocytes that may produce patches, plaques, tumors, erythroderma, and, ultimately, systemic dissemination. Treatment selection is generally guided by institutional experience, patient preference, and toxicity profile, as data from phase III clinical trials are limited. Effective topical treatments currently include mechlorethamine (Mustargen), carmustine (BCNU, BiCNU), corticosteroids, bexarotene (Targretin, a novel rexinoid), psoralen plus ultraviolet A, ultraviolet B, and total-skin electron-beam radiotherapy. Effective systemic treatments include interferon, retinoids, bexarotene, denileukin diftitox (Ontak), extracorporeal photopheresis, chemotherapy, and high-dose chemotherapy with allogeneic bone marrow transplant. Each of these treatments is discussed in detail, followed by specific recommendations for each stage of mycosis fungoides.

Original languageEnglish (US)
Pages (from-to)1419-1428
Number of pages10
JournalONCOLOGY
Volume17
Issue number10
StatePublished - Oct 2003
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Management of mycosis fungoides: Part 2. Treatment'. Together they form a unique fingerprint.

Cite this